Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 01, 2025 16:30 ET | Source: Castle Biosciences, Inc.

Castle Biosciences’ Founder, President and CEO Derek Maetzold Honored with the CEO of the Year Award by The CEO Magazine

Castle Biosciences' Founder, President & CEO Derek Maetzold awarded CEO of the Year by The CEO Magazine
September 23, 2025 07:00 ET | Source: Castle Biosciences, Inc.

Castle Biosciences Honored with a Greater Pittsburgh Top Workplaces 2025 Award

Castle Biosciences has been recognized as a Greater Pittsburgh Top Workplace by The Pittsburgh Post-Gazette
September 17, 2025 07:00 ET | Source: Castle Biosciences, Inc.

Castle Biosciences Named One of Newsweek’s America’s Greatest Companies 2025

Castle Biosciences has been included in the inaugural 2025 America’s Greatest Companies list, published by Newsweek.
September 09, 2025 07:00 ET | Source: Castle Biosciences, Inc.

New Data at American Foregut Society's 2025 Annual Meeting Demonstrates TissueCypher® Can Detect High-Risk Barrett’s Esophagus Patients Not Identified by Pathology to Support Improved Care Decisions

Castle will share new data on its TissueCypher Barrett’s Esophagus test via a podium presentation on Sept. 13 at the AFS 2025 Annual Meeting.
August 25, 2025 07:00 ET | Source: Castle Biosciences, Inc.

New Evidence Published Supporting Use of DecisionDx®-SCC Test in Guiding and Improving Treatment Pathway Decisions in NCCN High-Risk Cutaneous Squamous Cell Carcinoma

Castle announced the publication of two new studies related to its DecisionDx-SCC test for patients with high-risk cutaneous squamous cell carcinoma.
August 21, 2025 07:00 ET | Source: Castle Biosciences, Inc.

Castle Biosciences to Participate in Upcoming Investor Conferences

Castle Biosciences will participate in three investor conferences in September
August 04, 2025 16:05 ET | Source: Castle Biosciences, Inc.

Castle Biosciences Reports Second Quarter 2025 Results

Delivered Q2 2025 revenue of $86 million Q2 2025 total test reports for our core revenue drivers (DecisionDx®-Melanoma, TissueCypher®) increased 33% over Q2 2024 Raising full-year 2025 revenue...
July 29, 2025 07:00 ET | Source: Castle Biosciences, Inc.

Castle Biosciences to Present at the Canaccord Genuity 45th Annual Growth Conference

Castle Biosciences' executive management will present a company overview at the Canaccord Genuity 45th Annual Growth Conference Aug. 12, 2025 at 12:30pm ET
July 25, 2025 07:00 ET | Source: Castle Biosciences, Inc.

Castle Biosciences’ Founder, President and CEO Derek Maetzold Named a Most Admired CEO by the Houston Business Journal

Castle announced that its chief executive officer Derek Maetzold has been named a 2025 Most Admired CEO by the Houston Business Journal.
July 23, 2025 07:00 ET | Source: Castle Biosciences, Inc.

FDA Grants Breakthrough Device Designation to Castle Biosciences’ DecisionDx®-Melanoma Test

Castle announced that its DecisionDx®-Melanoma test has been granted Breakthrough Device designation from the U.S. Food and Drug Administration (FDA).